A reciprocal relationship exists between non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) and cyclooxygenase-2

Cancer Letters

Volumn 282, Issue 2, 2009, Pages 152-158

  Iguchi, Genzo ^a,b   Chrysovergis, Kali ^a   Lee, Seong Ho ^c   Baek, Seung Joon ^c   Langenbach, Robert ^a   Eling, Thomas E ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Colorectal cancer; COX 2; GDF 15; NAG 1

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT ACTIVATED PROTEIN 1; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER TISSUE; COLON CARCINOGENESIS; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; WILD TYPE;

ANIMALS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DINOPROSTONE; GENE EXPRESSION REGULATION; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; INTESTINAL POLYPS; MICE; MICE, INBRED C57BL; PYRAZOLES; SULFONAMIDES;

MUS;

EID: 67649933557     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.03.006     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer Statistics. CA Cancer J. Clin. 58 (2008) 71-96
2. Wang D., and DuBois R.N. Prostaglandins and cancer. Gut 55 (2006) 115-122
3. Torrance C.J., Jackson P.E., Montgomery E., Kinzler K.W., Vogelstein B., Wissner A., Nunes M., Frost P., and Discafani C.M. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 6 (2000) 1024-1028
4. Thun M.J., Namboodiri M.M., Calle E.E., Flanders W.D., and Heath Jr. C.W. Aspirin use and risk of fatal cancer. Cancer Res. 53 (1993) 1322-1327
5. Saha D., Roman C., and Beauchamp R.D. New strategies for colorectal cancer prevention and treatment. World J. Surg. 26 (2002) 762-766
6. Wang D., Buchanan F.G., Wang H., Dey S.K., and DuBois R.N. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res. 65 (2005) 1822-1829
7. Castellone M.D., Teramoto H., and Gutkind J.S. Cyclooxygenase-2 and colorectal cancer chemoprevention: the beta-catenin connection. Cancer Res. 66 (2006) 11085-11088
8. Phillips R.K., Wallace M.H., Lynch P.M., Hawk E., Gordon G.B., Saunders B.P., Wakabayashi N., Shen Y., Zimmerman S., Godio L., Rodrigues-Bigas M., Su L.K., Sherman J., Kellof G., Levin B., and Steinbach G. FAP Study Group, A randomized, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase-2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50 (2002) 857-860
9. Baek S.J., Kim K.S., Nixon J.B., Wilson L.C., and Eling T.E. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and anti-tumorigenic activities. Mol. Pharmacol. 59 (2001) 901-908
10. Baek S.J., Kim J., Nixon J.B., DiAugustine R.P., and Eling T.E. Expression of NAG-1, a transforming growth factor-β superfamily member, by troglitazone requires the early growth response gene EGR-1. J. Biol. Chem. 279 (2004) 6883-6892
11. Baek S.J., and Eling T.E. Changes in gene expression contribute to cancer prevention by COX inhibitors. Prog. Lipid Res. 45 (2006) 1-16
12. Baek S.J., Okazaki R., Lee S.H., Martinez J., Kim J.S., Yamaguchi K., Mishina Y., Martin D.W., Shoieb A., McEntee M.F., and Eling T.E. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 131 (2006) 1553-1560
13. Kim K.S., Baek S.J., Flake G.P., Loftin C.D., Calvo B.F., and Eling T.E. Expression and regulation of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) in human and mouse tissue. Gastroenterology 122 (2002) 1388-1398
14. Chulada P.C., Thompson M.B., Mahler J.F., Doyle C.M., Gaul B.W., Lee C., Tiano H.F., Morham S.G., Smithies O., and Langenbach R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in min mice. Cancer Res. 60 (2000) 4705-4708
15. Hull M.A., Booth J.K., Scott N., Bonifer C., Markham A.F., and Coletta P.L. Cyclooxygenase-2 is up-regulated and localized to macrophages in the intestine of min mice. Brit. J. Cancer 79 (1999) 1399-1405
16. Williams C.S., Luongo C., Radhika A., Zhang T., Lamps L.W., Nanney L.B., Beauchamp R.D., and DuBois R.N. Elevated cyclooxygenase-2 levels in min mouse adenomas. Gastroenterology 111 (1996) 1134-1140
17. Langenbach R., Morham S.G., Tiano H.F., Loftin C.D., Ghanayem B.I., Chulada P.C., Mahler J.F., Lee C.A., Goulding E.H., Kluckman K.D., Kim H.S., and Smithies O. Prostaglandin synthase-1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83 (1995) 483-492
18. Morham S.G., Langenbach R., Mahler J., and Smithies O. Characterization of prostaglandin H synthase 2 deficient mice and implications for mechanisms of NSAID action. Adv. Exp. Med. Biol. 407 (1997) 131-138
19. Kargman S.L., O'Neill G.P., Vickers P.J., Evans J.F., Mancini J.A., and Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 55 (1995) 2556-2559
20. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
21. Min/+ mice. Cancer Res. 62 (2002) 403-408
22. 2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ. Cancer Cell 6 (2004) 285-295
23. Maier T.J., Janssen A., Schmidt R., Geisslinger G., and Grösch S. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J. 19 (2005) 1353-1355
24. Pang R.P., Zhou J.G., Zeng Z.R., Li X.Y., Chen W., Chen M.H., and Hu P.J. Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through AKT/GSK3beta/NAG-1 pathway. Cancer Lett. 251 (2007) 268-277
25. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., and Chen C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking AKT activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 275 (2000) 11397-11403
26. Yamaguchi K., Lee S.H., Eling T.E., and Baek S.J. Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3β pathway. J. Biol. Chem. 279 (2004) 49617-49623
27. Bottone Jr. F.R., Moon Y., Kim J.S., Alston-Mills B., Ishibashi M., and Eling T.E. The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3). Mol. Cancer Ther. 4 (2005) 693-703
28. Lee S.H., Yamaguchi K., Kim J.S., Eling T.E., Safe S., Park Y., and Baek S.J. Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner. Carcinogenesis 27 (2006) 972-981
29. Buchanan F.G., Holla V., Katkuri S., and Matta P. Targeting cyclooxygenase-2 and epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res. 67 (2007) 9380-9388
30. Baek S.J., Horowitz J.M., and Eling T.E. Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter. Basal transcription is mediated by Sp1 and Sp3. J. Biol. Chem. 276 (2001) 33384-33392
31. Δ716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 87 (1996) 803-809
32. Fujino H., Xu W., and Regan J.W. Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phophatydlinositol-3 kinase and extracellular signal-related kinases. J. Biol. Chem. 278 (2003) 12151-12156
33. Buchanan F.G., Wang D., Bargiacchi F., and DuBois R.N. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J. Biol. Chem. 278 (2003) 35451-35457